Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Shares rose 6.6% Monday on new partnership strategy outlined at J.P. Morgan conference. Sanofi deal and cost cuts drive ...

Novavax faces significant financial challenges, with high leverage and declining revenue growth. While strategic partnerships and asset restructuring provide some optimism, the overall outlook remains ...

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference.

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. Novavax (NASDAQ: NVAX) was once a leading contender to ...

Novavax (NVAX +3.02%) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, ...

Shah Capital frustrated with Novavax's weak COVID-19 vaccine sales Hedge fund increases stake to 8.3%, urges sale to large pharma Novavax's COVID vaccine sales lag behind competitors Nov 13 (Reuters) ...

Adjusted Total Revenue is a non-GAAP financial measure. Adjusted Total Revenue is total revenue excluding Sanofi Supply Sales, Sanofi Royalties and Sanofi Influenza-COVID-19 Combination and Matrix-M ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald initiated coverage of Novavax, Inc. (NASDAQ:NVAX) with an Overweight rating and a ...

Fintel reports that on October 24, 2025, Cantor Fitzgerald initiated coverage of Novavax (NasdaqGS:NVAX) with a Overweight recommendation. Analyst Price Forecast Suggests 59.05% Upside As of September ...